Propel Bio Management »

Tscan Therapeutics shares owned by Propel Bio Management

Quarter-by-quarter ownership of Tscan Therapeutics (TCRX) shares owned by Propel Bio Management from 13F filings

Historical chart of Propel Bio Management investment in Tscan Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Tscan Therapeutics held by Propel Bio Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Tscan Therapeutics by Propel Bio Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $12M 2.1M 5.85
2024-03-31 $17M 2.1M 7.94
2023-12-31 $12M 2.1M 5.83

More positions owned by Propel Bio Management

Applied Therapeutics Comm (APLT)
Plains Gp Holdings Lp-cl Comm (PAGP)
Tscan Therapeutics Comm (TCRX)
Madrigal Pharmaceuticals Comm (MDGL)
Achieve Life Sciences Comm (ACHV)
Phathom Pharmaceuticals I Comm (PHAT)
Akero Therapeutics Comm (AKRO)
Avidity Biosciences Comm (RNA)
Ardelyx Comm (ARDX)
Abeona Therapeutics Comm (ABEO)
Fulcrum Therapeutics Comm (FULC)
Athira Pharma Comm (ATHA)
Telesat Corp Comm (TSAT)
Verrica Pharmaceuticals I Comm (VRCA)
Kura Oncology Comm (KURA)

View all positions for Propel Bio Management

Top funds holding Tscan Therapeutics

Lynx1 Capital Management
EcoR1 Capital
BlackRock
BlackRock
BVF
Baker Bros. Advisors
Vanguard Group
Propel Bio Management
Deer Management
Alphabet
Simplify Asset Management
Dr. Jeffrey R. Jay, M.D.
Geode Capital Management
Stempoint Capital
DC Funds

View all funds holding Tscan Therapeutics